Literature DB >> 15004085

Human monoclonal antibody fragment specific for glycoprotein G in herpes simplex virus type 2 with applications for serotype-specific diagnosis.

Francesca Bugli1, Stefania Manzara, Riccardo Torelli, Rosalia Graffeo, Rosaria Santangelo, Paola Cattani, Giovanni Fadda.   

Abstract

A combinatorial library was used to select a human monoclonal antibody fragment (Fab) with high affinity for G glycoprotein in herpes simplex virus type 2 (HSV-2). Tests with 112 clinical specimens demonstrated successful discrimination between HSV-2 and HSV-1, showing the potential of Fab as a low-cost tool for HSV subtyping in clinical diagnosis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15004085      PMCID： PMC356824          DOI： 10.1128/JCM.42.3.1250-1253.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  14 in total

1.  A novel expression vector for production of epitope-tagged recombinant Fab fragments in bacteria.

Authors:  R Burioni; F Bugli; N Mancini; G Fadda
Journal:  Hum Antibodies       Date:  2001

2.  Assembly of combinatorial antibody libraries on phage surfaces: the gene III site.

Authors:  C F Barbas; A S Kang; R A Lerner; S J Benkovic
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

3.  Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1.

Authors:  D J McGeoch; A Dolan; S Donald; F J Rixon
Journal:  J Mol Biol       Date:  1985-01-05       Impact factor: 5.469

4.  Localization of type-specific epitopes of herpes simplex virus type 2 glycoprotein G recognized by human and mouse antibodies.

Authors:  J A Liljeqvist; E Trybala; B Svennerholm; S Jeansson; E Sjögren-Jansson; T Bergström
Journal:  J Gen Virol       Date:  1998-05       Impact factor: 3.891

5.  Comparison of a direct antigen enzyme immunoassay, Herpchek, with cell culture for detection of herpes simplex virus from clinical specimens.

Authors:  L Verano; F J Michalski
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

Review 6.  Human monoclonal antibodies: recent achievements.

Authors:  D R Burton; C F Barbas
Journal:  Hosp Pract (Off Ed)       Date:  1994-11-15

7.  A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.

Authors:  D R Burton; C F Barbas; M A Persson; S Koenig; R M Chanock; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

8.  Human monoclonal antibodies against a plethora of viral pathogens from single combinatorial libraries.

Authors:  R A Williamson; R Burioni; P P Sanna; L J Partridge; C F Barbas; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

9.  Recombinant human Fab to glycoprotein D neutralizes infectivity and prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro.

Authors:  R Burioni; R A Williamson; P P Sanna; F E Bloom; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

10.  Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.

Authors:  C F Barbas; J E Crowe; D Cababa; T M Jones; S L Zebedee; B R Murphy; R M Chanock; D R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205
View more
  2 in total

1.  Generation of Fab fragment-like molecular recognition proteins against staphylococcal enterotoxin B by phage display technology.

Authors:  Yuji Urushibata; Kunihiko Itoh; Motohiro Ohshima; Yasuo Seto
Journal:  Clin Vaccine Immunol       Date:  2010-09-15

Review 2.  Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.

Authors:  Zhongyu Zhu; Ponraj Prabakaran; Weizao Chen; Christopher C Broder; Rui Gong; Dimiter S Dimitrov
Journal:  Virol Sin       Date:  2013-04-11       Impact factor: 4.327
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.